Smoldering Multiple Myeloma Smm clinical trials

Explore recruiting smoldering multiple myeloma smm clinical trials.

Recruiting smoldering multiple myeloma smm studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Smoldering Multiple Myeloma Smm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

Denmark, Sweden, Czechia, Belgium, Hungary, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Denmark, Germany, Hungary, Greece, Norway, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Smoldering Multiple Myeloma Smm trials by city

Smoldering Multiple Myeloma Smm clinical trials

Recruiting smoldering multiple myeloma smm studies right now

A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Also recruiting in Europe

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Smoldering Multiple Myeloma Smm trials by city

Other conditions